Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:48 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,638 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One MORE Clear all
Completed Phase 3 Interventional Results available

Naproxen Sodium Extended-Release Actual Use Study

NCT00751400
View directory record Official record
Conditions
Pain
Interventions
Naproxen Sodium ER (BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
24
States / cities
Anaheim, California • Oceanside, California • San Dimas, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Nov 3, 2026, 11:48 AM EST
Terminated Phase 4 Interventional Results available

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

NCT01547728
View directory record Official record
Conditions
Thrombophilia Due to Acquired Antithrombin III Deficiency
Interventions
Recombinant antithrombin (rhAT)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Nov 3, 2026, 11:48 AM EST
Completed Not applicable Interventional Results available

VISIBILITY™ Iliac Study

NCT01402700
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication
Interventions
Visi-Pro™ Balloon Expandable Stent System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Gradual vs. Abrupt Cessation Treatment for Smoking

NCT00297492
View directory record Official record
Conditions
Smoking Cessation
Interventions
Reduction Phone Counseling, Abrupt Phone Counseling, Minimal Abrupt Phone Counseling, Pre-Quit Nicotine Lozenges, Post-Quit Nicotine Lozenges
Behavioral · Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Nov 3, 2026, 11:48 AM EST
Not listed Not applicable Interventional

Family History Study on Cancer Risk

NCT04145388
View directory record Official record
Conditions
Lynch Syndrome, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Family Characteristics, Genetic Predisposition
Interventions
online cancer risk assessment, Usual care
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
25 Years to 75 Years
Enrollment
18,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 2 Interventional

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT00831051
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003, Morphine sulfate, Oxycodone HCl, Oxycodone HCl 4mg
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Anaheim, California • Owings Mills, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 1 Interventional

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

NCT02116712
View directory record Official record
Conditions
Pulmonary Lymphangioleiomyomatosis
Interventions
Saracatinib
Drug
Lead sponsor
Tony Eissa
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Nov 3, 2026, 11:48 AM EST
Completed Not applicable Interventional Results available

Dexcom G6 Observational Study

NCT03832907
View directory record Official record
Conditions
Diabetes
Interventions
Dexcom G6 CGM - Continues Glucose Monitoring sensor system, POC BG - Point-of-Care Blood Glucose monitoring
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Nov 3, 2026, 11:48 AM EST
Active, not recruiting Not applicable Interventional

ResIlience-based Stigma REdUction Program ("Rise-up")

NCT05174936
View directory record Official record
Conditions
HIV/AIDS, Stigma, Social, Emotional Adjustment
Interventions
PLWH intervention, Family member intervention, Healthcare provider intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 3, 2026, 11:48 AM EST
Completed Not applicable Interventional

Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device

NCT04008537
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Pelvis, Cancer of Abdomen, Cancer of Thorax
Interventions
Ring gantry kV-CBCT combined with linear accelerator
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Nov 3, 2026, 11:48 AM EST
Completed Not applicable Interventional Results available

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

NCT03647475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Combination Product
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 3, 2026, 11:48 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Rapamycin for Prevention of Chronic Graft-Versus-Host Disease

NCT00623012
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Rapamycin, Tacrolimus
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 2 Interventional Results available

Trial of High-Dose Rifampin in Patients With TB

NCT01408914
View directory record Official record
Conditions
Tuberculosis
Interventions
Higher-Dose Rifampin
Drug
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 3, 2026, 11:48 AM EST
Completed Not applicable Interventional

IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study

NCT01166516
View directory record Official record
Conditions
Prolonged Air Leak
Interventions
Treatment with HUD IBV Valve System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Springfield, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 1 Interventional Results available

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

NCT03468426
View directory record Official record
Conditions
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
Interventions
BI 836880, Ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude

NCT05037032
View directory record Official record
Conditions
Altitude, Sleep Apnea, Central
Interventions
Naltrexone Pill, Placebo
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Nov 3, 2026, 11:48 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Disorders Management, Health and Safety in Police

NCT00207285
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Screening and Treatment of Sleep Disorders
Behavioral · Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Nov 3, 2026, 11:48 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Testing Responses of Young Adults to Intervention Messages for Promoting Physical Activity Trial

NCT05794178
View directory record Official record
Conditions
Physical Inactivity, Weight Gain
Interventions
Education, Activity tracker, Text messaging (random timing and selection), Text messaging (precision dosing)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 29 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 11:48 AM EST
Active, not recruiting No phase listed Observational

Pro-active Genetic Testing in Kidney Transplant Patients

NCT05298904
View directory record Official record
Conditions
Kidney Transplant
Interventions
Genetic Health Screen Panel
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Nov 3, 2026, 11:48 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Erdafitinib Intravesical Delivery System
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 1 Interventional

18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

NCT02717572
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Fludeoxyglucose F 18, Positron Emission Tomography, Computerized Tomography, Magnetic Resonance Imaging
Radiation · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Nov 3, 2026, 11:48 AM EST
Recruiting Phase 1 Interventional

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 3, 2026, 11:48 AM EST
Active, not recruiting Phase 1 Interventional

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

NCT04620603
View directory record Official record
Conditions
Cutaneous Malignant Melanoma, Renal Cell Cancer, Urothelial Cancer of Renal Pelvis
Interventions
Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy
Radiation · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 3, 2026, 11:48 AM EST
Completed Phase 2 Interventional Results available

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions
ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Nov 3, 2026, 11:48 AM EST